‘Don’t Buy the Dip,’ Says Morgan Stanley About Hims & Hers Stock
Hims & Hers Health (NYSE:HIMS) shares were on a massive run, but that momentum hit a wall recently. Since its peak on ...
Nasdaq12d
Hims & Hers Stock Gains 8.6% in Three Months: How to Play It?
HIMS, in September, had announced access to the most common compounded GLP-1 subscriptions for $99 a month for eligible U.S. military, veterans, teachers, nurses and first responders. The company ...
Business Insider28d
Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — again
Hims' GLP-1 drugs start at $199 a month, while Wegovy and Ozempic cost over $900 a month — though the price many patients pay depends on their insurance. Earlier this month, Hims ran a Super ...
Hims & Hers Health (HIMS) Shares Spike with Compounded Drug Strategy for GLP-1s
Hims & Hers Health (HIMS) stock enjoyed a 10% jump in price last week on news that the company plans to continue offering compounded ...
Yahoo Finance28d
HIMS Stock Declines Following Q4 Earnings Miss, Gross Margin Contracts
Hims & Hers Health, Inc. HIMS delivered an earnings per share (EPS) of 11 cents in fourth-quarter 2024, compared with the year-ago period’s EPS of a penny. However, the metric missed the Zacks ...
NBC 10 Philadelphia29d
Hims & Hers shares tumble after company misses on margin, says may stop selling some weight loss drugs
In May, Hims & Hers started prescribing compounded semaglutide, the active ingredient in Novo Nordisk's blockbuster GLP-1 medications Ozempic ... in the coming month or two that they will need ...
Modern Healthcare29d
Hims & Hers pivots as semaglutide shortage ends
Direct-to-consumer telehealth company Hims & Hers is forging ahead in the aftermath of the semaglutide shortage ending last week. Hims & Hers faces new headwinds in its weight management segment ...